Authors:
Alberto Puccini, Joanne Xiu, Arielle Lutterman Heeke, Andreas Seeber, Richard M. Goldberg, Wafik S. El-Deiry, Stephan V Liu, Sarah Sammons, Emil Lou, Philip Agop Philip, John Marshall, Anthony Frank Shields, Heinz-Josef Lenz, Thomas J. Herzog, W. Michael Korn, Mohamed E Salem
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective therapies for some patients with both germline and somatic BRCA1/2 mutations (MTs) or with homologous recombination repair deficiency (HRD). We aimed to characterize molecular differences between BRCA1 and BRCA2 MTs and their prognostic and/or predictive impact on PARPi outcomes in various cancer subtypes using real world data (RWD).
Download Publication
